Markets:

Overview

News

Currencies

International

Treasuries

Puma Biotechnology Inc - Common Stock (NQ:PBYI)

7.626 -0.154 (-1.98%)

Streaming Delayed Price Updated: 2:29 PM EDT, Apr 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Puma Biotechnology Inc - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Puma Biotechnology Reports First Quarter 2022 Financial Results

May 05, 2022

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology Announces Publication of Neratinib Abstract Titles for the 2022 ASCO Annual Meeting

April 27, 2022

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results

April 21, 2022

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

April 05, 2022

From Puma Biotechnology, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Monday ↗

February 14, 2022

During Monday's session, 291 companies made new 52-week lows. Also check out this: Insiders Buying These 4 Penny Stocks Noteable 52-Week Lows And Highs: SAP (...

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

March 03, 2022

Gainers Puma Biotechnology (NASDAQ:PBYI) ...

Via Benzinga

The Daily Biotech Pulse: NuCana Shelves Biliary Tract Cancer Study, Tricida Data Readout Pushed Back Due to Ukrainian Crisis, Synlogic Names New CFO ↗

March 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus NuCana Discontinues Biliary Tract Cancer Study Following Futility Analysis...

Via Benzinga

Puma Biotechnology's Earnings: A Preview ↗

March 02, 2022

Puma Biotechnology (NASDAQ:PBYI) is set to give its latest quarterly earnings report on Thursday, 2022-03-03. Here's what investors need to know before the announcement. Analysts...

Via Benzinga

The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗

February 27, 2022

Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...

Via Benzinga

Earnings Scheduled For March 3, 2022 ↗

March 03, 2022

Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban...

Via Benzinga

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Results

February 16, 2022

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

February 03, 2022

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

January 20, 2022

From Puma Biotechnology, Inc.

Via Business Wire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

January 13, 2022

Gainers Stealth BioTherapeutics (NASDAQ:MITO

Via Benzinga

The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact ↗

January 13, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Says Lead Monoclonal Antibody Effective Against Omicron Variant Adagio...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

January 13, 2022

Good morning, investor! We're starting off the day right with a look at the biggest pre-market stock movers for Thursday!

Via InvestorPlace

20 Stocks Moving in Thursday's Pre-Market Session ↗

January 13, 2022

Gainers BTCS Inc. (NASDAQ: BTCS) rose 41% to $9.45 in pre-market trading after jumping 19% on Wednesday. Adagio Therapeutics, Inc. (NASDAQ: ADGI) rose 22.8% to $7.16 in pre-...

Via Benzinga

Puma Biotech's Nerlynx Included In NCCN Guidelines For Breast Cancer ↗

January 13, 2022

The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) has been updated for breast cancer treatment and includes two...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

January 12, 2022

Gainers Biomerica (NASDAQ:BMRA) stock inc...

Via Benzinga

Puma Biotechnology’s NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer

January 12, 2022

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology Releases Updated Corporate Presentation

January 10, 2022

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology to Present at the H.C. Wainwright BioConnect Conference

January 04, 2022

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology Presents Updates from the SUMMIT Trial at the 2021 SABCS Annual Meeting

December 10, 2021

From Puma Biotechnology, Inc.

Via Business Wire

The Daily Biotech Pulse: Lilly Sings Metabolic Disorder Drug Pact, Moderna Reports Positive Flu Vaccine Data, Halozyme To Buy Back Shares ↗

December 10, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Angion Biomedica's ANG-3777 Does Not Meet Primary Endpoint In Mid-Stage...

Via Benzinga

The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More ↗

December 06, 2021

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...

Via Benzinga

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

December 03, 2021

From Puma Biotechnology, Inc.

Via Business Wire

The Daily Biotech Pulse: Kura's Blood Cancer Drug Study Gets Partial Clinical Hold, Takeda FDA Nod, Puma Breast Cancer Treatment Gets Patent Extension ↗

November 24, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Puma Biotech Announces Receipt Of Patent Extension For Breast Cancer Drug By...

Via Benzinga

Topics Intellectual Property

Puma Biotechnology Announces U.S Patent Term Extension for NERLYNX® (neratinib)

November 23, 2021

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotech's Neratinib Fails To Extend Overall Survival In Brain Cancer Trial ↗

November 22, 2021

Puma Biotechnology Inc (NASDAQ: PBYI) announced interim data from the neratinib arm of Phase 2 INSIGhT Trial in newly diagnosed unmethylated glioblastoma with IDH...

Via Benzinga

Puma Biotechnology Presents Data from the Neratinib Arm of the INSIGhT Trial at the 2021 SNO Annual Meeting

November 20, 2021

From Puma Biotechnology, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.